Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H32N6O3 |
Molecular Weight | 416.518 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCn3c(=O)n(CC)nn3)COC
InChI
InChIKey=IDBPHNDTYPBSNI-UHFFFAOYSA-N
InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
Molecular Formula | C21H32N6O3 |
Molecular Weight | 416.518 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Alfentanil is an opioid analgesic with a rapid onset of action. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Alfentanil, marketed under the trade name Alfenta, Rapifen in Australia is indicated for the management of postoperative pain and the maintenance of general anesthesia.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ALFENTA Approved UseAlfentanil HCl injection is indicated: as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen. as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia. as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required. as the analgesic component for monitored anesthesia care (MAC). Launch Date5.36198414E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7598917 |
0.54 mg single, nasal dose: 0.54 mg route of administration: Nasal experiment type: SINGLE co-administered: |
ALFENTANIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1241.2 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7598917 |
0.54 mg single, nasal dose: 0.54 mg route of administration: Nasal experiment type: SINGLE co-administered: |
ALFENTANIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1985.7 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7598917 |
0.54 mg single, intravenous dose: 0.54 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ALFENTANIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
59.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7598917 |
0.54 mg single, nasal dose: 0.54 mg route of administration: Nasal experiment type: SINGLE co-administered: |
ALFENTANIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60.1 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7598917 |
0.54 mg single, intravenous dose: 0.54 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ALFENTANIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% |
ALFENTANIL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15557344/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15557344/ Page: 8.0 |
yes | |||
yes | likely (co-administration study) Comment: Concomitant use of Alfentanil HCl Injection with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of Alfentanil HCl Injection; discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in Alfentanil HCl Injection-treated patients may increase alfentanil plasma concentrations and prolong opioid adverse reactions Page: 1.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. | 2001 |
|
Choice of the hypnotic and the opioid for rapid-sequence induction. | 2001 |
|
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. | 2001 |
|
Tracheal intubation without muscle relaxant--a technique using sevoflurane vital capacity induction and alfentanil. | 2001 Aug |
|
A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. | 2001 Aug |
|
Total intravenous anesthesia versus single breath technique and anesthesia maintenance with sevoflurane for bariatric operations. | 2001 Aug |
|
Relative sensitivity to alfentanil and reliability of current perception threshold vs von Frey tactile stimulation and thermal sensory testing. | 2001 Dec |
|
Comparison of alfentanil and morphine in the prehospital treatment of patients with acute ischaemic-type chest pain. | 2001 Dec |
|
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. | 2001 Dec |
|
Response surface modeling of alfentanil-sevoflurane interaction on cardiorespiratory control and bispectral index. | 2001 Jun |
|
Comparison of the intubating laryngeal mask airway with the fiberoptic intubation in anticipated difficult airway management. | 2001 Jun |
|
[Factors influencing early extubation after open heart surgery]. | 2001 Jun 10 |
|
The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. | 2001 May |
|
Does discontinuation of desflurane at the time of neostigmine administration speed recovery from cisatracurium block compared to that with a propofol-based technique? | 2001 May |
|
Neural mechanisms in the cardiovascular responses to acute central hypovolaemia. | 2001 May-Jun |
|
The effects of remifentanil on epileptiform discharges during intraoperative electrocorticography in patients undergoing epilepsy surgery. | 2001 Oct |
|
Inhalation versus total intravenous anesthesia for lumbar disc herniation: comparison of hemodynamic effects, recovery characteristics, and cost. | 2001 Oct |
|
Stability of sufentanil in human plasma samples. | 2001 Oct |
|
The role of drug-lipid interactions on the disposition of liposome-formulated opioid analgesics in vitro and in vivo. | 2001 Oct |
|
Experience with an anesthesiologist interventional model for endoscopy in a pediatric hospital. | 2001 Sep |
|
Intraoperative small-dose ketamine enhances analgesia after outpatient knee arthroscopy. | 2001 Sep |
|
[Comparative studies of patient positioning for lumbar intervertebral disk operation]. | 2002 |
|
A randomized study of the efficacy and recovery of remifentanil-based and alfentanil anaesthesia with desflurane or sevoflurane for gynecological surgery. | 2002 |
|
Effect of sevoflurane/nitrous oxide versus propofol anaesthesia on somatosensory evoked potential monitoring of the spinal cord during surgery to correct scoliosis. | 2002 Apr |
|
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. | 2002 Apr |
|
Alfentanil and sufentanil in fast-track anesthesia for coronary artery bypass graft surgery. | 2002 Apr |
|
A new paradigm for the closed-loop intraoperative administration of analgesics in humans. | 2002 Apr |
|
Analgesia for shock wave lithotripsy. | 2002 Apr |
|
Comparison of effects of remifentanil, alfentanil and fentanyl on cardiovascular responses to tracheal intubation in morbidly obese patients. | 2002 Feb |
|
Bispectral index variations during tracheal suction in mechanically ventilated critically ill patients: effect of an alfentanil bolus. | 2002 Feb |
|
[Sedation analgesia in interventional radiology]. | 2002 Feb |
|
Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials. | 2002 Feb |
|
Pain model and fuzzy logic patient-controlled analgesia in shock-wave lithotripsy. | 2002 Jan |
|
Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia. | 2002 Jan |
|
Bispectral Index (BIS) may not predict awareness reaction to intubation in surgical patients. | 2002 Jan |
|
Relaxation music decreases the dose of patient-controlled sedation during colonoscopy: a prospective randomized controlled trial. | 2002 Jan |
|
Effects of adding alfentanil or atracurium to lidocaine solution for intravenous regional anaesthesia. | 2002 Jul |
|
Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. | 2002 Jul |
|
A new highly reliable instrument for the assessment of pre- and postoperative gynecological pain. | 2002 Jul |
|
Improved long-lasting postoperative analgesia, recovery function and patient satisfaction after inguinal hernia repair with inguinal field block compared with general anesthesia. | 2002 Jul |
|
Psychomotor performance after short-term anaesthesia. | 2002 Jun |
|
Postoperative nausea and vomiting after total intravenous anesthesia with propofol and remifentanil or alfentanil: how important is the opioid? | 2002 Jun |
|
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly. | 2002 Mar |
|
Total intravenous anesthesia for intraoperative monitoring of the motor pathways: an integral view combining clinical and experimental data. | 2002 Mar |
|
Respiratory response to skin incision during anaesthesia with infusions of propofol and alfentanil. | 2002 May |
|
Comparison of hemodynamics, recovery profile, and early postoperative pain control and costs of remifentanil versus alfentanil-based total intravenous anesthesia (TIVA). | 2002 May |
|
Co-administration of alfentanil-propofol improves laryngeal mask airway insertion compared to fentanyl-propofol. | 2002 May |
|
Mild core hypothermia and anesthetic requirement for loss of responsiveness during propofol anesthesia for craniotomy. | 2002 May |
|
Target-controlled versus manually-controlled infusion of propofol for direct laryngoscopy and bronchoscopy. | 2002 May |
|
Relative reinforcing effects of three opioids with different durations of action. | 2002 May |
Sample Use Guides
Spontaneously Breathing/Assisted Ventilation Induction of Analgesia: 8 to 20 mcg/kg
Maintenance of Analgesia: 3 to 5 mcg/kg q 5 to 20 min or 0.5 to 1 mcg/kg/min
Total dose: 8 to 40 mcg/kg
Assisted or Controlled Ventilation
- Assisted or Controlled Ventilation Incremental Injection
(To attenuate response to laryngoscopy and intubation) Induction of Analgesia: 20 to 50 mcg/kg
Maintenance of Analgesia: 5 to 15 mcg/kg q 5 to 20 min
Total dose: Up to 75 mcg/kg
Assisted or Controlled Ventilation
- Continuous Infusion
(To provide attenuation of response to intubation and incision) Induction of Analgesia: 50 to 75 mcg/kg
Maintenance of Analgesia: 0.5 to 3 mcg/kg/min (Average rate 1 to 1.5 mcg/kg/min) Infusion rates are variable and should be titrated to the desired clinical effect. See Infusion Dosage Guidelines Below
Total dose: Dependent on duration of procedure
Anesthetic Induction Induction of Anesthesia: 130 to 245 mcg/kg Administer slowly (over 3 minutes).
Maintenance of Anesthesia: 0.5 to 1.5 mcg/kg/min or general anesthetic.
Infusion rates are variable and should be titrated to the desired clinical effect. See Infusion Dosage Guidelines Below
Total dose: Dependent on duration of procedure
At these doses truncal rigidity should be expected and a muscle relaxant should be utilized.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17279089
Alfentanil (10 uM ) significantly increased contraction of TNF-alpha and IL-1beta treated cells via a small increase in the Ca(2+) transient and a larger increase in myofilament Ca(2+) sensitivity, effects that were not blocked by 10 uM naloxone, a broad spectrum opioid receptor antagonist.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 11:18:49 UTC 2021
by
admin
on
Sat Jun 26 11:18:49 UTC 2021
|
Record UNII |
1N74HM2BS7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
List_of_fentanyl_analogues
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
FDA ORPHAN DRUG |
206405
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
NDF-RT |
N0000175690
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
FDA ORPHAN DRUG |
206505
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
WHO-VATC |
QN01AH02
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
WHO-ATC |
N01AH02
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
DEA NO. |
9737
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
||
|
NDF-RT |
N0000175684
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
51263
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
480
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | RxNorm | ||
|
Alfentanil
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
DB00802
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
ALFENTANIL
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
CHEMBL634
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
7108
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
C61626
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
ALFENTANIL
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | While alfentanil tends to cause fewer cardiovascular complications than other similar drugs such as fentanyl and remifentanil, it tends to give stronger respiratory depression and so requires careful monitoring of breathing and vital signs. Almost exclusively used by anesthesia providers during portions of a case where quick, fast acting (though not long lasting) pain control is needed (i.e. during a nerve block, head pinning etc..) Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage. Alfentanil is a restricted drug which is classified as Schedule II in the USA, according to the U.S. DEA website. Alfentanil was discovered at Janssen Pharmaceutica in 1976. | ||
|
114
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
SUB05317MIG
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
M1499
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | Merck Index | ||
|
71195-58-9
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
71195-58-9
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
D015760
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
1N74HM2BS7
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
6789
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY | |||
|
4818
Created by
admin on Sat Jun 26 11:18:50 UTC 2021 , Edited by admin on Sat Jun 26 11:18:50 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Alfentanil is relatively distinctive among CYP3A substrates, in that the metabolic capacity (in vitro intrinsic clearance) of CYP3A5 equaled or exceeded that of CYP3A4.
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
FECAL; URINE
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
Alfentanil is relatively distinctive among CYP3A substrates, in that the metabolic capacity (in vitro intrinsic clearance) of CYP3A5 equaled or exceeded that of CYP3A4.
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||